Technology & Science
Aug. 28, 2014
Despite GAIN Act, antibiotic patents face setbacks
New guidelines may make it significantly more difficult to obtain patent protection for purified natural products and their derivatives. By David Hoffmeister, Vern Norviel, Richard Torczon, Prashant Girinath and Charles Andres
There is an urgent need for the discovery and development of novel antibiotics to treat bacterial pathogens that are resistant to one or more commercially available antibiotics. Total annual costs of antibiotic resistance mortality and morbidity are estimated to be as high as $20 billion for direct health care and an additional $35 billion in lost ...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In